Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F.
Saleh MN, et al. Among authors: infante jr.
Clin Cancer Res. 2021 Oct 1;27(19):5236-5247. doi: 10.1158/1078-0432.CCR-21-0715.
Clin Cancer Res. 2021.
PMID: 34301750
Free PMC article.
Clinical Trial.